Trapidil

Trapidil

Clinical data
Trade names	Rocornal, Avantrin, Travisco
AHFS/Drugs.com	International Drug Names
Routes of administration	By mouth
ATC code	C01DX11 ( WHO )
Legal status
Legal status	US:Not approved In general: ℞ (Prescription only)
Identifiers
IUPAC name N,N-Diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
CAS Number	15421-84-8  N
PubChem CID	5531
ChemSpider	5330  N
UNII	EYG5Y6355E
CompTox Dashboard (EPA)	DTXSID0045416
ECHA InfoCard	100.035.834
Chemical and physical data
Formula	C10H15N5
Molar mass	205.265 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(CC)c1cc(nc2n1ncn2)C
InChI InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3 N Key:GSNOZLZNQMLSKJ-UHFFFAOYSA-N N
NY  (what is this?)    (verify)

Trapidil is used in the treatment of chronic stable angina pectoris. It is currently marketed in Japan under the brand name Rocornal. ^[1]

An analog was assigned the codename AR 12-456. ^[2]

Pharmacology

Based on cell free in vitro activity assays, trapidil at therapeutic concentrations causes selective phosphorylation of cellular proteins through positive modulation of regulatory subunit RII(α/β) containing protein kinase A (PKA). ^{[3] [4]} At higher, non-physiologically relevant concentrations, which are generally not achieved after administration of therapeutic doses, non-selective inhibition of phosphodiesterases occurs. ^[4] Further, the previous documented activities as an antagonist of platelet-derived growth factor ^[5] are abolished when a PKA inhibitor is administered, suggesting that these noted activities are PKA mediated. ^[4] At these higher concentrations, ^[6] additional effects have been noted including vasodilation and inhibition of platelet aggregation ^{[7] [8]}

References

1. "ロコルナール錠100mg | 持田製薬株式会社". med.mochida.co.jp. Retrieved 2025-10-09.
2. Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A (1985). "Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells". Biomedica Biochimica Acta. 44 (5): K37 –K41. PMID   2415119.
3. Sichelschmidt OJ, Hahnefeld C, Hohlfeld T, Herberg FW, Schrör K (June 2003). "Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity". Cardiovascular Research. 58 (3): 602–610. doi:10.1016/S0008-6363(03)00261-X. PMID   12798433.
4. Bönisch D, Weber AA, Wittpoth M, Osinski M, Schrör K (August 1998). "Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A". Molecular Pharmacology. 54 (2): 241–248. doi:10.1124/mol.54.2.241. PMID   9687564.
5. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al. (December 1994). "Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica". Circulation. 90 (6): 2710–2715. doi: 10.1161/01.cir.90.6.2710 . PMID   7994812.
6. "Trapidil Professional Information (Summary of Product Characteristics/SPC)". Federal Institute for Drugs and Medical Devices (German). January 2019. Retrieved October 9, 2025.
7. Büyükafşar K, Yazar A, Düşmez D, Oztürk H, Polat G, Levent A (October 2001). "Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats". Pharmacological Research. 44 (4): 321–328. doi:10.1006/phrs.2001.0864. PMID   11592868.
8. Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, et al. (March–April 2014). "Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit". Indian Journal of Pharmacology. 46 (2): 207–210. doi: 10.4103/0253-7613.129320 . PMC   3987192 . PMID   24741195.